Mayo Clinic Finds Drug Combo Reverses Kidney Damage

More than 12 million Americans with diabetic kidney disease just got a dose of hope from Mayo Clinic researchers who found a way to reverse damage from stubborn cells that refuse to die.

The research team tested a combination of dasatanib, a cancer drug, and quercetin, a natural plant compound. Together, they targeted senescent cells, nicknamed "zombie cells" because they stick around in tissues long after they should have died naturally.

These zombie cells are troublemakers. They release harmful substances that cause inflammation and damage healthy tissue, speeding up aging and disease throughout the body.

Dr. LaTonya Hickson, a kidney specialist at Mayo Clinic in Florida, led the study published in eBioMedicine. Her team gave the combination therapy for a short time to test subjects with diabetic kidney disease and saw remarkable results.

The treatment reduced the number of zombie cells, lowered inflammation, and boosted protective factors in the kidneys. Even better, kidney function actually improved after the therapy.

"It was important to prove that this one-time, short-course treatment has an effect on the kidneys," says Dr. Xiaohui Bian, the study's lead author. The researchers accomplished this without needing invasive procedures.

Diabetic kidney disease is the leading cause of kidney failure in the United States. Current treatments can slow down the loss of kidney function, but doctors have no cure to offer patients.

Why This Inspires

This discovery matters because it represents a completely new approach to treating kidney disease. Instead of just slowing down damage, the therapy appears to reverse it by removing the cells causing harm.

The treatment course is short and uses compounds that already exist. Dasatanib is already approved for cancer treatment, and quercetin occurs naturally in foods like onions, apples, and berries.

Dr. Hickson's team had already shown in a pilot study with human patients that the combination reduced zombie cells in skin and fat tissue. This new research confirms the therapy works directly on the kidneys, the organ that matters most for these patients.

The findings open the door for larger clinical trials that could bring this treatment to the millions of people facing kidney failure. For patients who currently have few options beyond dialysis or transplant, this research offers something precious: a reason to believe their kidneys might heal.